Approaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments
|
|
- Alexandrina Burns
- 5 years ago
- Views:
Transcription
1 Approaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments Kris Thayer, National Center for Environmental Assessment (NCEA) Integrated Risk Information System (IRIS) Division Director Advancing Disease Modeling in Animal-Based Research in Support of Precision Medicine October 5-6, 2017 Office of Research and Development NCEA, IRIS
2 Created in 1985 to foster consistency in the evaluation of chemical toxicity across the Agency. IRIS assessments contribute to decisions across EPA and other health agencies Clean Air Act (CAA), Safe Drinking Water Act (SDWA), Food Quality Protection Act (FQPA), Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), Resource Conservation and Recovery Act (RCRA), Toxic Substances Control Act (TSCA) Comprehensive assessment of hazard and toxicity values Noncancer: Reference Doses (RfDs) and Reference Concentrations (RfCs). Cancer: Oral Slope Factors (OSFs) and Inhalation Unit Risks (IURs). IRIS is the only federal program to provide toxicity values for both cancer and noncancer effects. IRIS assessments undergo a rigorous, multi-step review process with opportunities for public input IRIS assessments have no direct regulatory impact until they are combined with Extent of exposure to people, cost of cleanup, available technology, etc. Regulatory options, which are the purview of EPA s program offices. 1
3 Toxicity Value Definitions Reference Dose/Concentration (non-cancer): An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral/inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark dose, with uncertainty factors generally applied to reflect limitations of the data used. [Durations include acute, short-term, subchronic, and chronic] Oral Slope Factor: is an estimate of the increased cancer risk from oral exposure to a dose of 1 mg/kg-day for a lifetime. The OSF can be multiplied by an estimate of lifetime exposure (in mg/kg-day) to estimate the lifetime cancer risk. Inhalation Unit Risk: is an estimate of the increased cancer risk from inhalation exposure to a concentration of 1 µg/m 3 for a lifetime. The interpretation of inhalation unit risk would be as follows: if unit risk = 2 10 ⁶ per µg/m³, 2 excess cancer cases (upper bound estimate) are expected to develop per 1,000,000 people if exposed daily for a lifetime to 1 µg of the chemical per m³ of air. The IUR can be multiplied by an estimate of lifetime exposure (in µg/m 3 ) to estimate the lifetime cancer risk 2
4 Assessments Conducted Using Systematic Review Methods Systematic Review Scoping Systematic Review Protocol Literature Inventory Study Evaluation Data Extraction Evidence Integration Derive Toxicity Values Assessment Initiated Assessment Developed Initial Problem Formulation Literature Search Refined Analysis Plan Organize Hazard Review Evidence Analysis and Synthesis Select and Model Studies Most pertinent to today s presentation on approach to integrating evidence Evidence integration is qualitative in IRIS assessments, expressed in context of confidence: Strongest evidence Weakest evidence Quantitative methods are being explored in NCEA e.g., Bayesian methods of combining data from human and other species 3
5 Individual Study Evaluation Scoping Systematic Review Protocol Literature Inventory Study Evaluation Data Extraction Evidence Integration Derive Toxicity Values Assessment Initiated Assessment Developed Initial Problem Formulation Literature Search Refined Analysis Plan Organize Hazard Review Evidence Analysis and Synthesis Select and Model Studies General approach same for human and animal studies Evaluation process focused on: Internal validity/bias Sensitivity Applicability (relevance to the question) Reporting quality 4
6 Overview of Study Evaluation in IRIS Individual study level domains Animal Reporting Quality Selection or Performance Bias Confounding/Variable Control Reporting or Attrition Bias Exposure Methods Sensitivity Outcome Measures and Results Display Other Epidemiological Exposure measurement Outcome ascertainment Population Selection Confounding Analysis Sensitivity Domain judgements Good Adequate Poor Critically Deficient Judgement Good Adequate Poor Critically Deficient Interpretation Appropriate study conduct relating to the domain & minor deficiencies not expected to influence results. A study that may have some limitations, but not likely to be severe or to have a substantive impact on results. Identified biases or deficiencies interpreted as likely to have had a substantial impact on the results or prevent reliable interpretation of study findings. A flaw that is so serious that the study could not be used. Rating Interpretation Overall study rating High Medium Low Uninformative High Medium Low Uninformative No notable deficiencies or concerns identified; potential for bias unlikely or minimal and sensitive methodology. Possible deficiencies or concerns noted, but resulting bias or lack of sensitivity would be unlikely to be of a substantive degree. Deficiencies or concerns were noted, and the potential for substantive bias or inadequate sensitivity could have a significant impact on the study results or their interpretation. Serious flaw(s) makes study results unusable for hazard identification 5
7 Individual Epidemiological Study Examples Medium confidence Uninformative 6
8 Across Study Evaluations 7 Study 1 Study 2 Study 3 Study 4 Study 5 Study 6
9 Within Evidence Stream Synthesis Scoping Systematic Review Protocol Literature Inventory Study Evaluation Data Extraction Evidence Integration Derive Toxicity Values Assessment Initiated Assessment Developed Initial Problem Formulation Literature Search Refined Analysis Plan Organize Hazard Review Evidence Analysis and Synthesis Select and Model Studies Synthesis of evidence is more than counting the number of positive and negative studies Consider the influence of bias and sensitivity when describing study results and synthesizing evidence Synthesis should primarily be based on studies of medium and high confidence (when available) Use structured framework to aid in transparency 8
10 Within Evidence Stream Considerations Epidemiology evidence Risk of Bias Animal toxicology evidence Sensitivity Directness/Applicability Consistency Effect magnitude/ precision Biological gradient/ dose-response Coherence Informative human and animal health effect evidence is analyzed and synthesized separately. Mechanistic evidence is synthesized that informs the conclusions regarding the human and animal health effect evidence. 9
11 Synthesizing Evidence on Health Effects Organization and Structure What outcomes are relevant to each health hazard domain and at what level (e.g., health effect or subgroupings) should synthesis occur? What populations were studied (e.g., general population, occupations, life stages, species, etc.) Can study results be described across varying exposure patterns, levels, duration or intensity? Are there differences in the confidence in study results for different outcomes, populations, or exposure? Does toxicokinetic information influence differences in responses across route of exposure, other aspects of exposure, or life stages? 10
12 Moving from Synthesis to Integration Scoping Systematic Review Protocol Literature Inventory Study Evaluation Data Extraction Evidence Integration Derive Toxicity Values Assessment Initiated Assessment Developed Initial Problem Formulation Literature Search Refined nalysis Plan Organize Hazard Review Evidence Analysis and Synthesis Select and Model Studies Step 1: Within Evidence Stream Judgements Results of Human Health Effect Study Synthesis Results of Animal Health Effect Study Synthesis Step 2: Across Evidence Stream Integration Results of Synthesis of Mechanistic Evidence Informing the Human and Animal Syntheses 11
13 Evidence Profile Tables to Summarize Evidence Synthesis and Integration Judgements Studies and confidence (risk of bias, sensitivity) Factors that increase confidence [Health Effect or Outcome Grouping] Evidence from Human Studies (Route) References Study confidence and explanation Study design description Consistency Dose response gradient Coherence of observed effects (apical studies) Effect size (magnitude, severity) Biological plausibility Low risk of bias/ high quality Insensitivity of null/ negative studies Factors that decrease confidence Unexplained inconsistency Imprecision Indirectness/ applicability Poor study quality/ high risk of bias Other (e.g., Single/Few Studies; small sample size) Evidence demonstrating implausibility Summary of findings Results information (general endpoints affected/ unaffected) across studies Human evidence informing biological plausibility: discuss how mechanistic data influenced the within stream judgement (e.g., evidence of precursors in exposed humans). Could be multiple rows (e.g., grouped by study confidence or population) if this informs results heterogeneity Within stream evidence strength judgements Describe confidence in evidence from human studies, and primary basis: Strongest evidence Weakest evidence Inference across evidence streams Describe assumptions and degree of support from mechanistic evidence Final evidence integration conclusion Describe conclusion(s) and primary basis for the integration of all available evidence (e.g., across human, animal, and mechanistic): Strongest Conclusion Weakest Conclusion Evidence for an Effect in Animals (Route) References Study confidence and explanation Study design description Consistency and Replication Dose response gradient Coherence of observed effects (apical studies) Effect size (magnitude, severity) Biological plausibility Low risk of bias/ high quality Insensitivity of null/ negative studies Unexplained inconsistency Imprecision Indirectness/ applicability Poor study quality/ high risk of bias Other (e.g., Single/Few Studies; small sample size) Evidence demonstrating implausibility Results information (general endpoints affected/ unaffected) across studies Evidence informing biological plausibility for effects in animals: discuss how mechanistic data influenced the within stream judgement (e.g., evidence of coherent molecular changes in animal studies) Could be multiple rows (e.g., by study confidence, species, or exposure duration) if this informs results heterogeneity Describe confidence in evidence for an effect in animals, and primary basis: Strongest evidence Weakest evidence 12
14 Example Evidence Profile Table Studies Factors that increase confidence Factors that decrease confidence Summary of findings Within stream confidence judgement Inferences across streams Hazard assessment conclusion Chemical X (Health Outcome Y) Human (oral) Case Series Study 1 Cross sectional Study 2 Few studies Low number of exposed cases (insensitivity) Lack of dose response Studies found no significant correlations with chemical X exposure and health outcome y INDETERMINATE Findings in animals presumed relevant to humans (no evidence to the contrary); coherent evidence from mechanistic studies mammalian and nonmammalian models. Risk of bias and sensitivity High risk of bias. Animal (oral) Short term Study 1 (rat) Study 2 (rat) Subchronic Study 3 (rat) Study 4 (mouse) Developmental/Reproductive Study 5 (rat) Study 6 (rat) Study 7 (rat) Study 8 (mouse) Risk of bias and sensitivity Coherence among related endpoints Low risk of bias Dose response gradient Biological plausibility Small sample sizes in some studies Some unexplained inconsistency Similar pattern of changes in hormone A and hormone B were observed in study 1 and study 2. Effects on serum hormone levels are supported by histopathological changes in tissue A (study 1, study 3, study 4, study 5, study 6) and increased tissue A weight (study 1, study, 5, study 6, study 8). Evidence of dose response gradient in most studies reporting effects. Biological plausibility of the observed effects is supported by mechanistic studies in mammalian and nonmammalian models (see Section Mechanistic Evidence). MODERATE 13
15 Parting Thoughts State of science for evidence integration across animal and human studies largely qualitative; structured frameworks are becoming more common In environmental chemical assessments animal models are typically assumed relevant to human health unless data to contrary exist Considerations for importance of similarity in animal and human response may differ based on goals (therapeutic predictively versus identifying potential hazard) Exact findings in animals and humans not necessarily required in chemical assessments (e.g., tumor site concordance) Worth considering minimal data standards as journals develop guidance on amount/type of information shared via supplemental information 14
16 THANK YOU FOR YOUR ATTENTION Office of Research and Development NCEA, IRIS
Methodologies for development of human health criteria and values for the lake Erie drainage basin.
3745-1-42 Methodologies for development of human health criteria and values for the lake Erie drainage basin. [Comment: For dates of non-regulatory government publications, publications of recognized organizations
More informationPresenting Uncertainty in the Context of Toxicological, Biological Monitoring and Exposure Information. William H.
Presenting Uncertainty in the Context of Toxicological, Biological Monitoring and Exposure Information William H. Farland, PhD, ATS Presenting Risk Information and Uncertainty Concerns regarding how uncertainty
More informationCase Study Summary: Appendix: Evaluation of Hazard Range for Three Additional Chemicals: Tetrachloroethylene, Chromium (VI) and Arsenic.
Case Study Summary: Practical Guidance on the Development of a Non-cancer Hazard Range for Effective Risk Assessment and Risk Management of Contaminated Sites: A Case Study with Trichloroethylene and Other
More informationApplication of human epidemiological studies to pesticide risk assessment
Workshop What does the future hold for harmonised human health risk assessment of plant protection products? Application of human epidemiological studies to pesticide risk assessment Antonio F. Hernández,
More informationTetrachloroethylene: Integrated Risk Information System (IRIS) Draft Toxicological Review Kate Z. Guyton, PhD DABT
Tetrachloroethylene: Integrated Risk Information System (IRIS) Draft Toxicological Review Kate Z. Guyton, PhD DABT National Academy of Sciences Tetrachloroethylene Peer Review Panel November 13, 2008 NCEA
More informationDevelopment of NJ Human Health-based Criteria and Standards
Development of NJ Human Health-based Criteria and Standards Gloria Post NJDEP Office of Science Presented to: Public Health Standing Committee October 18, 2010 Human Health-based Criteria and Standards
More informationCHAPTER 8 RISK CHARACTERIZATION
CHAPTER 8 RISK CHARACTERIZATION This chapter describes the final step of the baseline health risk assessment process, risk characterization. In this step, the toxicity and exposure assessments are summarized
More informationTexas Commission on Environmental Quality
Roberta L. Grant, Susan L. Santos, Mike L. Dourson, Stephanie Shirley, Neeraja K. Erraguntla, R. Jeffrey Lewis, and Nancy B. Beck Society of Toxicology, March 22-26, 2015 San Diego, CA Texas Commission
More informationRisk Characterization
Risk Characterization 1 Learning Objectives By the end of this module, participants should have an understanding of: The purpose of risk characterization Integrating the results of hazard identification,
More informationCHAPTER 7 TOXICITY ASSESSMENT
CHAPTER 7 TOXICITY ASSESSMENT The purpose of the toxicity assessment is to assessment, the amount of new toxicological weigh available evidence regarding the potential evaluation of primary data required
More informationCHARACTERIZING THE IMPACTS OF UNCERTAINTY AND SCIENTIFIC JUDGMENT IN EXPOSURE LIMIT DEVELOPMENT
CHARACTERIZING THE IMPACTS OF UNCERTAINTY AND SCIENTIFIC JUDGMENT IN EXPOSURE LIMIT DEVELOPMENT Andrew Maier, Ph.D., CIH, DABT TERA Robert Sussman, Ph.D., DABT SafeBridge Consultants, Inc. Bruce Naumann,
More informationHuman Health Risk Assessment Overview [For the APS/OPP Roundtable]
Human Health Risk Assessment Overview [For the APS/OPP Roundtable] Christina Swartz, USEPA Nov. 12, 2008 [Slides Courtesy of Mike Metzger, USEPA] The Risk Assessment Paradigm: The Red Book Hazard Identification
More informationKey Aspects of U.S. EPA s External Review Draft Toxicological Review of Trichloroethylene (TCE)
Key Aspects of U.S. EPA s External Review Draft Toxicological Review of Trichloroethylene (TCE) Presentation for the Midwestern States Risk Assessment Symposium Weihsueh A. Chiu, PhD U.S. Environmental
More informationZinc: Issues and Update. Craig Boreiko, Ph.D. Ottawa May 2008
Zinc: Issues and Update Craig Boreiko, Ph.D. Ottawa May 2008 Topics Basics of zinc deficiency and essentiality Nutrition vs Toxicology Effects of elevated zinc intake Comparison of risk assessments Concluding
More informationPart 2. Chemical and physical aspects
Part 2. Chemical and physical aspects 12. Chemical and physical aspects: introduction 12.1 Background information used The assessment of the toxicity of drinking-water contaminants has been made on the
More informationGuidelines of the Scientific Committee on Food for the development of tolerable upper intake levels for vitamins and minerals
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Scientific Opinions C3 - Management of scientific committees II; scientific co-operation and networks Scientific Committee
More informationAddendum to the 12th Report on Carcinogens
Addendum to the 12th Report on Carcinogens Published by the U.S. Department of Health and Human Services, National Toxicology Program The twelfth edition of the National Toxicology Program (NTP) Report
More informationOverview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools: Opportunities and Challenges of Application in Developing DRIs
Workshop on Guiding Principles for the Inclusion of Chronic Diseases Endpoints in Future Dietary Reference Intakes (DRIs) Overview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools:
More informationSTUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH AN ACUTE REFERENCE DOSE
VICH GL54 (SAFETY) ARfD November 2016 For Implementation at Step 7 STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH AN ACUTE REFERENCE DOSE (ARfD)
More informationQuantitative Risk Assessment: An Overview and Discussion of Emerging Issues. Anne-Marie Nicol, PhD
Quantitative Risk Assessment: An Overview and Discussion of Emerging Issues Anne-Marie Nicol, PhD Today s talk Broader overview of Risk Assessment process (at the US EPA) Explanation of the 4 step formal
More informationThe Scientific Rationale for Deriving Database and Toxicodynamic Uncertainty Factors for Reproductive or Developmental Toxicants
1 2 3 4 6 7 The Scientific Rationale for Deriving Database and Toxicodynamic Uncertainty Factors for Reproductive or Developmental Toxicants 8 9 1 11 12 13 Prepared by Bernard Gadagbui Jay Zhao Andy Maier
More informationSubject: Assessing the Potential Risk of Human Exposure to Tetrachloroethylene (Perchloroethylene) and Formaldehyde
Memo Date: June 20, 2006 To: From: Shelly Burman, Minnesota Pollution Control Agency Hillary Carpenter, Health Risk Assessment Unit Subject: Assessing the Potential Risk of Human Exposure to Tetrachloroethylene
More informationDistinguishing between Mode and Mechanism of Action
Distinguishing between Mode and Mechanism of Action Michael Dourson Toxicology Excellence for Risk Assessment Center University of Cincinnati College of Medicine Conflict of Interest Statement The research
More informationRobert G. Sussman, Ph.D., DABT Managing Principal, Eastern Operations. SafeBridge Consultants, Inc. Mountain View, CA New York, NY Liverpool, UK
Robert G. Sussman, Ph.D., DABT Managing Principal, Eastern Operations SafeBridge Consultants, Inc. Mountain View, CA New York, NY Liverpool, UK Paracelsus (1493 1541) All substances are poisons; there
More information1, 2, 3-Trichloropropane (TCP): Assessment of Risks from Drinking Water
1, 2, 3-Trichloropropane (TCP): Assessment of Risks from Drinking Water 1, 2, 3-Trichloropropane (TCP): Assessment of Risks from Drinking Water Prepared for Alaimo Group (Engineers and Architects) 200
More informationRisk Assessment Report for AGSS-ICS
1. INTRODUCTION This Risk Assessment evaluated the human health risks from exposure during and after application of AGSS-ICS. This information will determine whether AGSS-ICS used to treat soil will present
More informationSafety Assessment of Hypobromous Acid (220 ppm as Br 2 ) Used as a Beef Carcass Wash
Safety Assessment of Hypobromous Acid (220 ppm as Br 2 ) Used as a Beef Carcass Wash Prepared for: Enviro Tech Chemical Services Modesto, CA Prepared by: Duncan Turnbull, DPhil, DABT Senior Science Advisor
More informationPublic Health Masters (MPH) Competencies and Coursework by Major
I. Master of Science of Public Health A. Core Competencies B. Major Specific Competencies i. Professional Health Education ii. iii. iv. Family Activity Physical Activity Behavioral, Social, and Community
More informationDose and Response for Chemicals
Dose and Response for Chemicals 5 5 DOSE AND RESPONSE FOR CHEMICALS All substances are poisons; there is none which is not a poison. The right dose differentiates a poison and a remedy. Paracelsus, 16th
More informationMathematical Framework for Health Risk Assessment
Mathematical Framework for Health Risk Assessment Health Risk Assessment Does a substance pose a health hazard and, if so how is it characterized? A multi-step process Risk Characterization MSOffice1 Hazard
More informationEnvironmental Risk Assessment Toxicity Assessment
Environmental Risk Assessment Toxicity Assessment UT Evening School Course Spring Semester 2000 Class #07 on February 29, 2000 Environmental Engineering EV595 Martin Clauberg, Ph.D. 1 Outline of discussion
More informationOPINION of the French Agency for Environmental and Occupational Health Safety
The Director General Maisons-Alfort, France, 15 June 2009 OPINION of the French Agency for Environmental and Occupational Health Safety Relating to establishing carcinogenic HTVs by inhalation for carbon
More informationPHO MetaQAT Guide. Critical appraisal in public health. PHO Meta-tool for quality appraisal
PHO MetaQAT Guide Critical appraisal in public health Critical appraisal is a necessary part of evidence-based practice and decision-making, allowing us to understand the strengths and weaknesses of evidence,
More informationMINNESOTA DEPARTMENT OF HEALTH STATEMENT OF NEED AND REASONABLENESS
MINNESOTA DEPARTMENT OF HEALTH STATEMENT OF NEED AND REASONABLENESS Proposed Permanent Rules Relating to Health Risk Values Minnesota Rules, Parts 4717.8000 to 4717.8600 INTRODUCTION The Minnesota Department
More informationUncertainty Characterization: The Role of Hypothesis-Based Weight of Evidence"
Uncertainty Characterization: The Role of Hypothesis-Based Weight of Evidence" Lorenz Rhomberg, PhD Gradient Corporation lrhomberg@gradientcorp.com 617-395-5552 LSRO / CHRA -- 23 May 2007 -- Washington
More informationOutline: risk assessment. What kind of environmental risks do we commonly consider? 11/19/2013. Why do we need chemical risk assessment?
Outline: Human health h and ecological l risk assessment Purpose of risk assessment Methodology for quantifying risk Case study: Children s exposure to As from CCA wood staircases Issues practical and
More informationLive WebEx meeting agenda
10:00am 10:30am Using OpenMeta[Analyst] to extract quantitative data from published literature Live WebEx meeting agenda August 25, 10:00am-12:00pm ET 10:30am 11:20am Lecture (this will be recorded) 11:20am
More informationEstablishing the Relevance of Health Hazard Data for GHS Classification: Adverse vs. Non-Adverse
Establishing the Relevance of Health Hazard Data for GHS Classification: Adverse vs. Non-Adverse Robert Roy, Ph.D. SCHC Fall Meeting Diplomate, American Board of Toxicology September 30, 2014 1 Disclaimer
More informationAlcohol interventions in secondary and further education
National Institute for Health and Care Excellence Guideline version (Draft for Consultation) Alcohol interventions in secondary and further education NICE guideline: methods NICE guideline Methods
More informationConsiderations in Toxicology Study Design and Interpretation: An Overview Gradient Corporation: Lewis, AS; Beyer, LA; Langlois, CJ; Yu, CJ; Wait, AD
Considerations in Toxicology Study Design and Interpretation: An Overview Gradient Corporation: Lewis, AS; Beyer, LA; Langlois, CJ; Yu, CJ; Wait, AD Introduction The use of animal data to evaluate the
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationBaseline Human Health Risk Assessment. Terrie Boguski, Skeo Solutions
Baseline Human Health Risk Assessment Terrie Boguski, Skeo Solutions Agenda 1. Purpose 2. Process 3. Models and methods 4. Research needed 5. Final report and decision making 2 Disclaimer TASC presentations
More informationProtocol 30 Classifying Substances as Carcinogenic May 2018
Carcinogenic substance should be added to this list as it is a definition provided in Procedure 8; however, the Procedure 8 definition of a carcinogenic substance obviously needs to be revised but unclear
More informationISPOR Task Force Report: ITC & NMA Study Questionnaire
INDIRECT TREATMENT COMPARISON / NETWORK META-ANALYSIS STUDY QUESTIONNAIRE TO ASSESS RELEVANCE AND CREDIBILITY TO INFORM HEALTHCARE DECISION-MAKING: AN ISPOR-AMCP-NPC GOOD PRACTICE TASK FORCE REPORT DRAFT
More information12 HEALTH RISK ASSESSMENT
12 HEALTH RISK ASSESSMENT 12.1 Introduction The control of health risks from the exposure to any physical, chemical or biological agent is informed by a scientific, ideally quantitative, assessment of
More informationHEALTH CONSULTATION. Tom Lea Park EL PASO COUNTY METAL SURVEY EL PASO, EL PASO COUNTY, TEXAS EPA FACILITY ID: TX
HEALTH CONSULTATION Tom Lea Park EL PASO COUNTY METAL SURVEY EL PASO, EL PASO COUNTY, TEXAS EPA FACILITY ID: TX0000605388 September 6, 2002 Prepared by: The Texas Department of Health Under a Cooperative
More informationCPH601 Chapter 3 Risk Assessment
University of Kentucky From the SelectedWorks of David M. Mannino 2013 CPH601 Chapter 3 Risk Assessment David M. Mannino Available at: https://works.bepress.com/david_mannino/64/ + Risk Assessment David
More informationCEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews
CEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews Since September 2013, the CEU has been responsible for pre-publication screening of new intervention
More informationHSIA Halogenated Solvents Industry Alliance, Inc.
HSIA Halogenated Solvents Industry Alliance, Inc. 1530 Wilson Boulevard, Arlington, VA 22209; Tel: 703-875-0683 Toxicological Review of Dichloromethane (Methylene Chloride) In Support of Summary Information
More informationScience Policy Notice
Science Policy Notice SPN2002-01 Children s Health Priorities within the Pest Management Regulatory Agency (publié aussi en français) January 3, 2002 This document is published by the Submission Coordination
More informationDEVELOPMENT OF THE CHROMIUM PUBLIC HEALTH GOAL
DEVELOPMENT OF THE CHROMIUM PUBLIC HEALTH GOAL Robert A. Howd, Ph.D. Chief, Water Toxicology Unit Office of Environmental Health Hazard Assessment, California Environmental Protection Agency Oakland and
More informationWhich delivers more mercury, dental amalgam or a tuna fish sandwich? G. Mark Richardson, Ph.D. Risklogic Scientific Services Inc., Ottawa, ON CANADA
Which delivers more mercury, dental amalgam or a tuna fish sandwich? By G. Mark Richardson, Ph.D. Risklogic Scientific Services Inc., Ottawa, ON CANADA Introduction The debate concerning mercury (Hg) exposure
More informationRisk Assessment and 09/13/07. Learning Objectives. Nature of Risk. Risk Assessment and Environmental Policy. Gene Schroder, PhD
Risk Assessment and Environmental Policy Risk Assessment and Environmental Policy Gene Schroder, PhD the dichotomy that exist between the perceptions of the public and the experts on which risks are important
More informationMr. Bruce Allen. Dr. Harvey Clewell.
Mr. Bruce Allen. Mr. Allen has 27 years of experience related to human and environmental health and safety. He has expertise as a biomathematician involved in risk assessment, modeling, statistical analysis,
More informationThought Starter Combined Exposures to Multiple Chemicals Second International Conference on Risk Assessment
Thought Starter Combined Exposures to Multiple Chemicals Second International Conference on Risk Assessment M.E. (Bette) Meek & A. Kortenkamp 1 Outline State of the Art Assessment of Mixtures (aka Combined
More informationOECD GUIDANCE DOCUMENT FOR THE DERIVATION OF AN ACUTE REFERENCE CONCENTRATION (ARfC) Revision History
OECD GUIDANCE DOCUMENT FOR THE DERIVATION OF AN ACUTE REFERENCE CONCENTRATION (ARfC) Revision History FIRST DRAFT 14 AUGUST 2009 SECOND DRAFT 6 AUGUST 2010 1 Table of contents GLOSSARY OF TERMS... 5 1
More informationNarrative overviews. Lesley Rushton Epidemiology and Public Health
Narrative overviews Lesley Rushton Epidemiology and Public Health l.rushton@imperial.ac.uk Carrying Out a Narrative Review task To investigate the likelihood that there is an association between an environmental
More informationRISK ASSESSMENT GUIDANCE FOR SUPPLEMENTAL GUIDANCE FOR INHALATION RISK ASSESSMENT SUPERFUND, PART F: Midwestern States Risk Assessment
RISK ASSESSMENT GUIDANCE FOR SUPERFUND, PART F: SUPPLEMENTAL GUIDANCE FOR INHALATION RISK ASSESSMENT Michael Sivak EPA Region 2 Superfund Program Midwestern States Risk Assessment Symposium - November
More informationThe Rule of Five: A Novel Approach to Derive PRGs. Marc S. Greenberg and David W. Charters
The Rule of Five: A Novel Approach to Derive PRGs Marc S. Greenberg and David W. Charters U.S. Environmental Protection Agency Environmental Response Team Edison, NJ USA greenberg.marc@epa.gov Objectives
More informationResearch in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research
Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research David Hickam, MD, MPH Director, Clinical Effectiveness & Decision Science Program April 10, 2017 Welcome!
More informationN-Methylneodecanamide (MNDA)
United States Prevention, Pesticides EPA-730-F-99-008 Environmental Protection And Toxic Substances July 1999 Agency (7505C) New Pesticide Fact Sheet Description of the Chemical N-Methylneodecanamide (MNDA)
More informationResults. NeuRA Hypnosis June 2016
Introduction may be experienced as an altered state of consciousness or as a state of relaxation. There is no agreed framework for administering hypnosis, but the procedure often involves induction (such
More informationDRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX
EUROPEAN COMMISSION Brussels, XXX C(2016) 3752 projet DRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX setting out scientific criteria for the determination of endocrine-disrupting properties pursuant
More informationCritical appraisal: Systematic Review & Meta-analysis
Critical appraisal: Systematic Review & Meta-analysis Atiporn Ingsathit MD.PhD. Section for Clinical Epidemiology and biostatistics Faculty of Medicine Ramathibodi Hospital Mahidol University What is a
More informationCopyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD
GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD ASSISTANT PROFESSOR DEPARTMENT OF CLINICAL EPIDEMIOLOGY AND BIOSTATISTICS, MCMASTER UNIVERSITY Nancy Santesso,
More informationIS AMBIENT HYDROGEN SULFIDE A RISK TO HUMAN HEALTH? Sarah R. Armstrong, M.S., D.A.B.T. Michael R. Ames, Sc.D. and Laura C. Green, Ph.D., D.A.B.T.
IS AMBIENT HYDROGEN SULFIDE A RISK TO HUMAN HEALTH? Sarah R. Armstrong, M.S., D.A.B.T. Michael R. Ames, Sc.D. and Laura C. Green, Ph.D., D.A.B.T. Cambridge Environmental Inc. 58 Charles St. Cambridge,
More informationWhat are the challenges in addressing adjustments for data uncertainty?
What are the challenges in addressing adjustments for data uncertainty? Hildegard Przyrembel, Berlin Federal Institute for Risk Assessment (BfR), Berlin (retired) Scientific Panel for Dietetic Foods, Nutrition
More informationSpecial Review Decision: Imazapyr
Re-evaluation Note REV2016-02 Special Review Decision: Imazapyr (publié aussi en français) 7 January 2016 This document is published by the Health Canada Pest Management Regulatory Agency. For further
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationControlled Trials. Spyros Kitsiou, PhD
Assessing Risk of Bias in Randomized Controlled Trials Spyros Kitsiou, PhD Assistant Professor Department of Biomedical and Health Information Sciences College of Applied Health Sciences University of
More informationCase Study Application of the WHO Framework for Combined Exposures. Presented by: M.E. (Bette) Meek University of Ottawa
Case Study Application of the WHO Framework for Combined Exposures Presented by: M.E. (Bette) Meek University of Ottawa bmeek@uottawa.ca WHO IPCS Framework for Combined Exposures Objectives Building on
More informationEFSA working group on BPA assessment protocol. Ursula Gundert-Remy Chair of the EFSA Working Group BPA assessment Protocol
EFSA working group on BPA assessment protocol Ursula Gundert-Remy Chair of the EFSA Working Group BPA assessment Protocol Workshop on BPA hazard assessment protocol Brussels, 14 September 2017 Acknowledgements
More informationEvidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co.
Evidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co. Meta-Analysis Defined A meta-analysis is: the statistical combination of two or more separate studies In other words: overview,
More informationBACKGROUND + GENERAL COMMENTS
Response on behalf of Sobi (Swedish Orphan Biovitrum AB) to the European Commission s Public Consultation on a Commission Notice on the Application of Articles 3, 5 and 7 of Regulation (EC) No. 141/2000
More informationEthylene Oxide
Ethylene Oxide 75-21-8 Hazard Summary The major use of ethylene oxide is as a chemical intermediate in the manufacture of ethylene glycol. Ethylene oxide is also used as a sterilizing agent for medical
More informationComments from PlasticsEurope
Polycarbonate/Bisphenol A Group Follow-up Meeting on the Web-Based Public Consulting on Bisphenol A Brussels, April 23 2014 Comments from PlasticsEurope Dieter Beyer Representing the Polycarbonate/Bisphenol
More informationINITIAL STATEMENT OF REASONS TITLE 27, CALIFORNIA CODE OF REGULATIONS
INITIAL STATEMENT OF REASONS TITLE 27, CALIFORNIA CODE OF REGULATIONS PROPOSED AMENDMENT TO: SECTION 25705(b) SPECIFIC REGULATORY LEVELS POSING NO SIGNIFICANT RISK GLYPHOSATE SAFE DRINKING WATER AND TOXIC
More informationPizza Pan Case Study
Session 4 Case Study of Risk Assessment and Management Pizza Pan Case Study Fernanda Takata The Dow Chemical Company, Product Stewardship and Regulatory Specialist 16 March, May, 2013 2011 Taipei Chile
More informationRisk Assessment Approaches for Nanomaterials
Risk Assessment Approaches for Nanomaterials Eileen D. Kuempel, PhD Nanotechnology Research Center Education and Information Division National Institute for Occupational Safety and Health The findings
More information: EPDM REPAIR TAPE - 6" CURED
SECTION 1 - PRODUCT IDENTIFICATION Trade name Product code COMPANY Telephone Emergency Phone: Product use : : 68106B503 : Tremco Incorporated 3735 Green Road Cleveland, OH 44122 : (216) 292-5000 8:30-5:00
More informationTNsG on Annex I Inclusion Revision of Chapter 4.1: Quantitative Human Health Risk Characterisation
TNsG on Annex I Inclusion Revision of Chapter 4.1: Quantitative Human Health Risk Characterisation These Technical Notes for Guidance were adopted during the 34 th meeting of representatives of Members
More informationObjectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions
Guidelines: Evidence or Expert opinion or???? Objectives Need for guidelines? Prakesh Shah Professor, Department of Pediatrics, Mount Sinai Hospital Institute of Health Policy Management and Evaluation
More informationA Framework for Patient-Centered Outcomes Research
A Framework for Patient-Centered Outcomes Research David H. Hickam, MD, MPH Director of Research Methodology, PCORI Baltimore, MD August 9, 2016 Session Faculty Disclosures David H. Hickam, MD, MPH No
More informationMeta-analysis of safety thoughts from CIOMS X
CIOMS Working Group X Meta-analysis of safety thoughts from CIOMS X Stephen.Evans@Lshtm.ac.uk Improving health worldwide www.lshtm.ac.uk Evans: ENCePP CIOMS Meta Analysis 1 Acknowledgements, conflicts,
More informationGlyphosate Hazard and Risk Assessment: A Comparison of the Approaches of Two International Agencies
Glyphosate Hazard and Risk Assessment: A Comparison of the Approaches of Two International Agencies David A. Eastmond Environmental Toxicology Graduate Program University of California, Riverside Glyphosate
More informationStakeholders consultations on Info Cards and Brief Profiles
Stakeholders consultations on Info Cards and Brief Profiles Workshop on Substance Brief Profiles 06 November 2014 Janne Kilpinen Tiago Pedrosa Contents 1 st Written Consultation Overview Main topics, main
More informationCRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG)
CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG) Atiporn Ingsathit MD, PhD. 1 Rationale for Clinical Practice Guidelines Worldwide concerns about: Unexplained variations in clinical practice Rising
More informationEvaluating the Quality of Evidence from a Network Meta- Analysis
Evaluating the Quality of Evidence from a Network Meta- Analysis Georgia Salanti 1, Cinzia Del Giovane 2, Anna Chaimani 1, Deborah M. Caldwell 3, Julian P. T. Higgins 3,4 * 1 Department of Hygiene and
More informationThe Director General Maisons-Alfort, 30 July 2018 OPINION. of the French Agency for Food, Environmental and Occupational Health & Safety
The Director General Maisons-Alfort, 30 July 2018 OPINION of the French Agency for Food, Environmental and Occupational Health & Safety on the development of chronic TRVs for the oral and respiratory routes
More informationEVALUATION OF POLYCYCLIC AROMATIC HYDROCARBONS IN CLAY TARGET FRAGMENTS AND SURFACE SOIL AT SHOT GUN RANGE SITES Presenter: Glenn Hoeger and Brian
EVALUATION OF POLYCYCLIC AROMATIC HYDROCARBONS IN CLAY TARGET FRAGMENTS AND SURFACE SOIL AT SHOT GUN RANGE SITES Presenter: Glenn Hoeger and Brian Magee ARCADIS/Malcolm Pirnie May 11, 2011 Objectives 1.
More informationDiscussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK
Discussion Meeting for MCP-Mod Qualification Opinion Request Novartis 10 July 2013 EMA, London, UK Attendees Face to face: Dr. Frank Bretz Global Statistical Methodology Head, Novartis Dr. Björn Bornkamp
More informationBfR Proposal for a Harmonised Procedure for Estimating the Dermal Absorption
FEDERAL INSTITUTE FOR RISK ASSESSMENT BfR Proposal for a Harmonised Procedure for Estimating the Dermal Absorption Lars Niemann Why is an accurate estimate of dermal absorption so critical? Exposure of
More informationDose Response Approaches for Nuclear Receptor Mediated Modes of Action Workshop Preliminary Report
Dose Response Approaches for Nuclear Receptor Mediated Modes of Action Workshop Preliminary Report Workshop Organizing Committee 2 Major Goals of the Workshop Determine whether the biology of nuclear receptors
More informationAPPENDIX IV.I.1. Delivery Truck HRA
APPENDIX IV.I.1 Delivery Truck HRA Diesel Particulate Matter (DPM) Health Risk Assessment (HRA) of Delivery Trucks from the Project at Pico and Sepulveda, Los Angeles, California Introduction This health
More informationDRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials
DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop
More informationDose-Response Relationship of Essential Metallic Elements. The Application of Categorical Regression Example: Copper
Dose-Response Relationship of Essential Metallic Elements The Application of Categorical Regression Example: Copper Problem: Dose-response relationship for essential trace elements is complex Highly Abnormal
More informationDevelopment of safe levels of elemental impurities
Development of safe levels of elemental impurities ICH Q3D MASSET Dominique Head of Pharmaceutical Quality Non Clinical and Viral Safety Department Evaluation division 5 april 2016 EMA London Safe Levels
More informationMATERIAL SAFETY DATA SHEET Consumer Product
Page 1 of 6 1. PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME: GENERAL USE: Nail Care PRODUCT DESCRIPTION: PRODUCT FORMULATION NAME: CHEMICAL FAMILY: Nail Care GENERIC NAME: Green Pigment MANUFACTURER
More informationChemical Name: Metolachlor ESA CAS: Synonyms: Ethanesulfonate degradate of metolachlor; CGA
2011 Health Risk Limits for Groundwater Health Risk Assessment Unit, Environmental Health Division 651-201-4899 651-201-5797 TDD Web Publication Date: March 21, 2011 Chemical Name: Metolachlor ESA CAS:
More informationTrials and Tribulations of Systematic Reviews and Meta-Analyses
Trials and Tribulations of Systematic Reviews and Meta-Analyses Mark A. Crowther and Deborah J. Cook St. Joseph s Hospital, Hamilton, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada Systematic
More information